Author: Kelley, S.W.
Paper Title Page
MOPAB412 Accelerator Production of Mo-99 Using Mo-100 1237
 
  • J.L. McCarter, M.J. Brennan, S.M. Burns, J.T. Harvey, S.W. Kelley, T.A. Montenegro, Q. Schiller
    NorthStar Medical Technologies, LLC, Beloit, USA
 
  Funding: DE-NA0001878
Tc-99m is an essential radionuclide for nearly 40,000 diagnostic nuclear medicine tests in the U.S. each day. Its daily production depends on Mo-99, which must be replenished weekly due to Mo-99’s 2.75 day half-life. Mo-99, in the past, was supplied from uranium fission production, depending on overseas nuclear reactors that average 50 years old. Their age in combination with shipment uncertainties make the availability of Mo-99 fragile and subject to severe shortages. The U.S. now has one domestic, FDA-approved supplier that produces Mo-99, NorthStar Medical Radioisotopes. Currently, NorthStar produces Mo-99 via the irradiation of Mo-98 in a nuclear reactor. In the future, NorthStar will also irradiate Mo-100 with accelerator created x-rays to produce Mo-99. This process will use 2 distinct, 40 MeV, 125 kW average electron accelerators, Rhodotrons produced by IBA. Accelerator produced Mo-99 has several advantages over that produced by reactors, including a dual supply and an ability to adjust irradiation timing to meet radiopharmacy demands, such as Sunday delivery. NorthStar is currently installing and commissioning this accelerator based system, entering production in late-2022.
 
poster icon Poster MOPAB412 [2.150 MB]  
DOI • reference for this paper ※ https://doi.org/10.18429/JACoW-IPAC2021-MOPAB412  
About • paper received ※ 24 May 2021       paper accepted ※ 07 June 2021       issue date ※ 19 August 2021  
Export • reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)